Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer

Inclusion Criteria

• Histologically or cytologically confirmed pancreatic adenocarcinoma which may be acquired using a fine needle aspiration.
• Not received any prior therapy.
• Established resectable pancreatic cancer based on radiographic imaging.
• Patients who will receive neoadjuvant therapy (chemoradiation) are eligible.
• Age ≥18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥60%).
• Have no active or chronic infection with HIV, Hepatitis B or Hepatitis C
• Life expectancy of greater than six months.
• Ability to understand and the willingness to sign a written informed consent document.
• Normal organ and marrow function as defined below:
• leukocytes ≥3,000/microliter (mcL)
• absolute neutrophil count ≥1,500/mcL
• platelets ≥100,000/mcL
• total bilirubin < 2 mg/dL or has demonstrated progressive decline within two weeks of biliary decompression to allow for appropriate gemcitabine dose modification.
• Aspartate Aminotransferase (AST)[Serum Glutamic Oxaloacetic Transaminase (SGOT] )/ Alanine Aminotransferase (ALT) [Serum Glutamic Pyruvic Transaminase(SGPT)] ≤3 × institutional upper limit of normal
• Creatinine clearance ≥60 mL/min/1.73 m^2

Exclusion Criteria

• Patients with more clinically advanced pancreatic cancer (borderline resectable, locally advanced, or metastatic).
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant women are excluded from this study because the effects of metakaryocidal agents have the potential for teratogenic or abortifacient effects.
• Previous history of other malignancy (other than cured basal or squamous cell carcinoma of the skin or cured in-situ carcinoma of the cervix) within two years of study enrollment.
• Active or chronic HIV, hepatitis B or hepatitis C.
• Patients who are receiving other investigational drugs or enrolled in other clinical trials.
• Inability to undergo scheduled blood acquisition per protocol.
• Drug specific exclusion including history of allergic reactions to tetracyclines.
• Prior treatment with doxycycline within a seven day washout period prior to initiating treatment with alternate antimetakaryocidal medication.